Best Healthcare Companies in Raleigh, United States
The 125 best Healthcare companies in Raleigh, United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Pathalys.
Ranked: Best Healthcare companies in Raleigh
| # | Company | Disclosed funding | Last round | Stage | Employees | Founded | Founder | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | PRA Health Sciences Global full-service CRO offering its services in 80+ countries globally | $2M | — | Acquired | 12,870 | 1976 | — | — | — |
| 2 | 3D Communications Provider of 3d communication services | — | — | Unfunded | — | 2003 | — | 150 patents Patents concentrated in electrical & electronics | — |
| 3 | Active Healthcare Provider of asthma therapy and diabetes management services | — | — | Unfunded | 7 | 1990 | — | — | — |
| 4 | Adroit Pharmaceutical Development Formulation and process technologies for inhalation and dermatological product development | — | — | Unfunded | — | 2002 | Keith Johnson Owner | — | — |
| 5 | Alliance of Disability Advocates Alliance of Disability Advocates (ADA) is the Federal Center for Independent Living serving Raleigh, Durham… | — | — | — | 35 | 1999 | — | — | — |
| 6 | Ally Homecare Provider of in-home non-medical personal care and assistance | — | — | Funding Raised | 4 | 2013 | — | — | — |
| 7 | Aloha Plus Retail store that offers a range of cannabinoids, including CBD, THC, Delta-8, HHC, CBG, CBN, and indoor hemp… | — | — | Unfunded | 1 | 2020 | — | — | — |
| 8 | Alpha Home Care Services Provider of personal, respite, and other home care services | — | — | Unfunded | — | 2001 | — | — | — |
Top 12 Healthcare companies in Raleigh
#1
Series C · Raleigh, North Carolina · founded 2020 · 4 employees$44Mraised▾
Developer of needle-free nasal spray for anaphylaxis and severe allergic reactions. The company focuses on creating accessible and user-friendly emergency medications. It develops dry powder nasal formulations to improve drug absorption and simplify emergency use. The goal is to provide temperature-stable, pain-free options for allergy emergencies.
- Aug 2025Series C$32.3M
- Jan 2025Seed$11M
- Feb 2023Conventional Debt$500K
- Jul 2021Conventional Debt$250K
#2
Series A · Raleigh, North Carolina · founded 2020 · 69 employees$37.7Mraised▾
CDMO offering services for cell and gene therapy products
- Jan 2025Series A$21M
- Oct 2022Conventional Debt$15.9M
- Mar 2022Series A$37.7M
#3
Series B · Raleigh, North Carolina · founded 2021 · 8 employees$105Mraised▾
Provider of CKD biotherapeutics development services
- Aug 2024Series B$105M
- Jan 2023Seed—
#4
Late Stage · Raleigh, North Carolina · founded 2014$50Mraised▾
Provider of clinical research data services for oncology & other therapeutic areas
- Sep 2024PE$50M
#5
Funding Raised · Raleigh, North Carolina · founded 2014 · 9 employees$18Mraised▾
AI-driven drug discovery for rare, neglected diseases, and toxicology solutions. The company leverages artificial intelligence and machine learning to accelerate the development of clinical candidates for unmet therapeutic needs. They offer software tools for predicting toxicity, visualizing molecular data, and building machine learning models. Their expertise extends to designing new molecules with desired properties, aiding pharmaceutical, consumer product, and other companies in their chemistry needs. They focus on advancing care for rare diseases through collaboration, innovation, and data-driven insights. They provide services like licensing agreements, strategic partnerships, and tailored contracting solutions. Their software can be used to design and score new compounds, calculate properties, or predict toxicities. They also offer software and machine learning models for licensing, enabling scientists to leverage their technologies.
- Mar 2024Grant (prize money)$1.8M
- Sep 2023Grant (prize money)$295.1K
- Apr 2022Grant (prize money)$256.2K
- Dec 2021Grant (prize money)$983.7K
#6
Series C · Raleigh, North Carolina · founded 2010 · 48 employees$93.8Mraised▾
Provider of patients medical informations
- Jan 2018Series C$4.5M
- May 2015Series C$50M
- Jun 2014Series B$4.3M
- Jul 2013Series B$10M
#7
Seed · Raleigh, North Carolina · founded 2008 · 46 employees$2.4Mraised▾
Manufacturer of precision optical components and assemblies for medical devices. It provides design and manufacturing services, specializing in surgical endoscopy, glass-to-metal seals, micro-optics, and thin-film coatings. The company offers complete manufacturing solutions, from design and development to testing and measurement, supporting the production of optical imaging and diagnostic devices. Its capabilities include precision laser welding and the creation of hermetic optical cells. The firm serves major medical original equipment manufacturers (OEMs).
- Apr 2022Seed$250K
- Aug 2018Seed$1.2M
- Nov 2017Seed$125K
- Aug 2016Seed$800K
#8
Series B · Raleigh, North Carolina · founded 2004 · 67 employees$17.6Mraised▾
Provider of multi-specialty ambulatory surgical services in an outpatient environment. The center offers surgical services with a trained staff. It adheres to quality control standards and guidelines established by an accreditation association. Specialties include general surgery, orthopedics, ophthalmology, otolaryngology, pain management, pediatric surgery, spine surgery, total joint replacement, and urology.
- May 2012Series B$17.6M
#9
Funding Raised · Raleigh, North Carolina · founded 2023$675Kraised▾
Developer of wearable sensor technology for physiological data and health insights. The company provides adaptable technologies delivering real-time data for health, performance, and discovery. Their sensor platforms offer data collection for clinical and academic studies. They support physiological monitoring through wearable solutions, enabling remote care.
- Jun 2023Grant (prize money)$575K
- Jun 2022Grant (prize money)$100K
#10
Series A · Raleigh, North Carolina · founded 2015 · 53 employees$7.5Mraised▾
Offers intellectual and developmental disabilities services
- May 2019Series A$7.5M
#11
Acquired · Raleigh, North Carolina · founded 1997$9Mraised▾
Ntouchresearch is a full service CRO. It offers complete clinical trial management services for phase I to post-approval Phase IV trials. These services include site management and monitoring, data management, biostatistics, health economics, and medical and regulatory affairs. All its facilities are ICH and GCP compliant.
- Feb 2000PE$8M
- 1998Unattributed$1M
#12
Public · Raleigh, North Carolina · founded 1998 · 6700 employees$4.5Mraised▾
INC Research is a full-service CRO offering clinical development services right from Phase I to Phase IV for biopharmaceutical and medical device industries. It offers customised phase I to phase IV programs in a wide range of therapeutic areas including oncology, CNS diseases, infectious diseases, endocrinology, immunology and inflammation, and paediatric and women’s health. The company offers its services through a therapeutically aligned delivery model and active engagement through its site relationships. INC Research is the first CRO to sponsor SCRS (Society of Clinical Research Sites) Scholarships and claims to be the first CRO to utilise Site Advocacy Groups. INC Research's CRO services portfolio includes clinical trial management (including patient recruitment and retention), data management and biostatistics, regulatory affairs, medical writing and post-approval services (Safety surveillance, health outcomes research etc.,). The Company was named “Best Contract Research Organization” in December 2015 by an independent panel for Scrip Intelligence. INC Research claims to be the only CRO to rank consistently among the top three CROs in all seven CenterWatch site relationship
- Dec 2017Grant (prize money)$4.5M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Healthcare coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.